The EFNB1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line. This product provides a heterogeneous pool of cells carrying targeted disruptions in the EFNB1 gene, enabling loss-of-function studies of ephrin-B1 without clonal selection artifacts. It is supplied as a ready-to-use polyclonal population suitable for a wide range of in vitro and in vivo assays.
The parental A-549 cell line was established from the lung adenocarcinoma tissue of a 58-year-old male and serves as a well-characterized in vitro model of human alveolar type II pulmonary epithelium. Widely employed in cancer biology and drug testing research, A-549 cells exhibit epithelial morphology and retain key features of adenocarcinoma, making them an ideal host for investigating tumor cell behavior and therapeutic responses.
EFNB1 encodes ephrin-B1, a membrane-bound ligand for Eph receptor tyrosine kinases that mediates bidirectional signaling. Ephrin-B1 engages EPHB1, EPHB2, EPHB3, and EPHA4 receptors and is regulated by upstream factors including TGFB1, WNT, FGF2, and TP53. Upon receptor binding, ephrin-B1 activates downstream targets such as SRC, PTK2, RHOA, CDC42, STAT3, and MAPK8, and couples to the MAPK/ERK, PI3K-Akt, and Rho GTPase pathways. Through adaptor proteins like NCK2 and interactions with SDCBP, CLDN1, and CLDN4, ephrin-B1 controls cell adhesion, migration, and cytoskeletal dynamics. Disruption of EFNB1 in these polyclonal knockout cells abolishes ligand expression, impairing ephrin-B1/Eph receptor-mediated forward and reverse signaling, which is expected to reduce migratory and invasive capacity.
In the A-549 lung adenocarcinoma context, loss of EFNB1 is particularly relevant for dissecting the role of ephrin-B1 in tumor progression and metastasis. Ephrin-B1 has been implicated in promoting aggressive phenotypes in lung adenocarcinoma, breast cancer, and melanoma, and its knockout provides a valuable model to examine how ephrin-Eph signaling contributes to cancer cell dissemination and survival. Moreover, since EPHB1 and other pathway components like PAK1, RAC1, MAPK1, and AKT1 are functionally linked to ephrin-B1, this knockout enables investigation of signaling networks that drive oncogenic processes. Researchers can use this model to assess the dependency of A-549 cells on ephrin-B1 for xenograft tumor growth and metastatic spread.
These polyclonal EFNB1 knockout A-549 cells are ideally suited for a variety of experimental applications, including wound healing and transwell assays to quantify migration and invasion changes, western blotting and immunofluorescence to probe alterations in Eph receptor signaling and downstream effectors, and cell adhesion assays. The cells can be employed in tumor xenograft studies to evaluate the impact of ephrin-B1 loss on in vivo growth and metastasis, or in drug response screens to identify synthetic lethal interactions with ephrin pathway inhibitors. Furthermore, RT-qPCR can be used to verify gene expression changes in the knockout background. For additional information or to discuss your specific research needs, please contact Ascent Research.
